TWST Twist Bioscience Corp Insider Trading

Twist Bioscience CEO Emily M. Leproust sold 18,880 shares at $95.00 under 10b5-1 plan; stock up 55.6% in 30 days.

Emily M. Leproust sold 18,880 shares at $95.00 on 2026-06-25, reducing her holdings from 842.9K to 824.0K shares, under a pre-arranged 10b5-1 trading plan adopted on 2025-05-27. The sale represents scheduled activity rather than a discretionary market decision. TWST has appreciated 55.6% over the preceding 30 days and 124.2% over the preceding 90 days, significantly outperforming her cross-ticker track record (average 30-day and 90-day returns of +14.1% and +14.6%, respectively after her prior 14 sells across all tickers). The company remains unprofitable with a net loss of $44.0M in the latest quarter, though revenue growth stands at 20.3% year-over-year. As a 10b5-1 execution, this transaction carries no inference about the executive's market timing or conviction at the point of filing.

Dennis Cho sold 14,205 shares of TWST at $89.75 under pre-arranged 10b5-1 plan; retains 105,141 shares.

This sale of 14,205 shares was executed under a 10b5-1 trading plan adopted on 2026-02-17, meaning it was scheduled rather than discretionary. The transaction occurred at $89.75, below the current price of $99.84 and the 52-week high of $104.23. While Twist Bioscience posted annual revenue growth of +20.3% and recent quarterly revenue of $110,715,000.00, the company reported net income of $-44,021,000.00 and remains unprofitable on a full-year basis. Cho retains 105,141 shares post-transaction, maintaining a substantial equity stake despite the scheduled disposition.

SVP HR Paula Green sold 26,137 shares at $81.62–$82.17 for $2.1M, retaining 120.7K shares

Paula Green, SVP of Human Resources, executed two separate sales totaling 26,137 shares for $2,134,487.77 on 2026-06-15, reducing her stake by 17.8% to 120,705 remaining shares. The sales at a blended average price of $81.67 occurred while TWST trades near its 52-week high (current price $82.87, -6.3% from peak), following a sharp 66.4% rally over the prior 30 days. Green's prior sell at this ticker on 2026-02-17 produced a negative 90-day return of -5.0%, consistent with her cross-ticker well-timed rate of 100.00% on prior sells. The company remains unprofitable (net income -$44.0M on revenue of $110.7M) despite 20.3% annual revenue growth, which provides limited fundamental support for sustained momentum following the recent gain.

TWST CEO Emily Leproust sells 16,470 shares for $1,118,554.58 via scheduled 10b5-1 plan; retains 846,872 shares + 75,439 options.

Emily M. Leproust, TWST CEO, executed 4 separate open-market sales totaling 16,470 shares for $1,118,554.58 on 2026-05-28 under a pre-arranged 10b5-1 trading plan adopted 2025-05-27. Prices ranged from $65.33 to $68.61 (blended average $67.91), near the current price of $67.86 and well above the 52-week low of $23.30. This is a 1.9% reduction of her non-derivative holdings, leaving her with 846,872 shares post-transaction. The sale follows modest near-term stock strength (+12.4% over 30 days, +45.5% over 90 days) but occurs at a company trading 4.5% below its 52-week high of $71.04. TWIST remains unprofitable (latest quarter net income $-44.0M) despite revenue growth of +20.3% year-over-year and latest quarterly revenue of $110.7M. Her prior sales at TWST have shown mixed near-term results (30-day returns: -8.2%, -7.2%, -9.5%, +1.8%, -2.1%), and her cross-ticker track record shows average 90-day return of +7.5% after sells. The scheduled nature of this sale under her 10b5-1 plan means the timing reflects pre-planned portfolio management rather than a discretionary decision responding to current conditions.

TWST CEO Emily Leproust sold 49,299 shares for $3,213,653.17 via 10b5-1 plan; retains 846,872 shares plus 208,835 option holdings.

CEO Emily M. Leproust executed 3 separate sales totaling 49,299 shares for $3,213,653.17 (blended average price $65.19) on May 26–27, 2026, as part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-27. This is a scheduled, non-discretionary transaction. Post-sale, she retains 846,872 non-derivative shares and 208,835 shares in derivative holdings (option pools), representing a -5.5% reduction in her non-derivative position. The current price of $69.03 is above the sale prices ($65.08–$66.28), reflecting a 16.7% gain in the stock over the past 30 days and +47.1% over 90 days. While her prior sales at TWST show mixed results (three recent sells in April 2026 followed by 30-day declines of -8.2%, -7.2%, and -9.5%), the structured nature of the 10b5-1 plan removes discretionary timing from this decision and positions it as a pre-planned liquidity event. The company remains unprofitable (net income $-44.0M on latest full-year basis) despite 20.3% annual revenue growth.

CEO Emily Leproust sold 9,671 shares at $65.24 blended average; stock now $58.85 (-6.9% from 52-week high), company unprofitable.

Emily Leproust, CEO of unprofitable Twist Bioscience, executed 3 separate sales totaling 9,671 shares for $630,957.35 across April 21-22, 2026, at prices ranging from $65.01 to $66.00. The stock has since declined to $58.85, 6.9% below its 52-week high of $63.20, suggesting the CEO may have sold near a local peak. Her cross-ticker track record shows a 0.00% well-timed sell rate (0 of prior 4 sells preceded subsequent 90-day declines), and at TWST specifically, 0 of 4 prior sales were well-timed at the 90-day mark—a consistent pattern of selling into strength rather than before downturns. She retains 858,887 shares post-transaction, a modest 1.1% reduction from her 868,558 share position. The company reported negative net income of $-30,507,000.00 on quarterly revenue of $103,698,000.00, indicating structural profitability challenges that merit investor attention despite 20.3% annual revenue growth.

SVP HR Paula Green sold 39,404 shares of TWST at $52.40; retains 126,041 shares after 23.8% reduction in holdings.

Paula Green, SVP of Human Resources, sold 39,404 shares for $2,064,769.60 on 2026-02-17, representing a 23.8% reduction in her prior holdings to 126,041 shares. The sale occurred near Twist Bioscience's 52-week high of $54.92, within 2.52 points of peak valuation. The broader context is material: the company generated $103.7M in quarterly revenue with annual growth of 20.3%, but reported a full-year net loss of $30.5M and remains unprofitable. This sale by a human resources executive—a non-operational role without direct business visibility—provides limited insight into management's assessment of product or commercial trajectory. The transaction's significance lies in its size and timing relative to market peaks rather than any strategic signal about company fundamentals.

Finn Patrick John (then-President/COO) sells 68,967 shares across 4 transactions on 2026-02-17 for $3,562,416.57 per 10b5-1 plan

Finn Patrick John, who was President and COO at the time of filing, executed 4 separate sales totaling 68,967 shares for $3,562,416.57 on 2026-02-17, reducing his holdings from 356,755 to 287,788 shares (-19.3%). The transactions were conducted at blended average price of $51.65 across four distinct price points ranging from $50.32 to $53.11. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-13, meaning it was scheduled and not discretionary. The substantial dollar volume and multi-tranche execution reflect a programmatic liquidation tied to a prearranged plan rather than an ad-hoc market decision.

Twist Bioscience COO Finn Patrick John sold 23,279 shares at $40.00 on 2026-01-13; stock up 32.6% over 30 days post-sale.

Finn Patrick John, President and COO, sold 23,279 shares at $40.00, reducing his holdings by -6.9% to 312,883 shares. The stock has appreciated 32.6% over the 30 days following the sale, and currently trades at $41.27, above the transaction price. His cross-ticker track record shows 3 prior sells with an average 90-day return of -9.6% and a 50.00% well-timed rate, indicating mixed timing performance. At TWST specifically, his prior two completed sells (2025-10-06 and 2025-05-08) produced a 90-day pattern of one well-timed outcome (negative return, -19.8% on 2025-05-08) and one neutral outcome (+0.6% on 2025-10-06). The company remains technically unprofitable on a full-year basis despite recent quarterly profitability and 20.3% annual revenue growth, trading at a P/E of 55.03. Post-transaction stock appreciation suggests this particular sale did not precede an anticipated decline.

TWST President/COO Finn Patrick John sold 20,000 shares at $32.31; stock down 28.7% in 90 days amid unprofitability

Finn Patrick John, the President and COO of Twist Bioscience, sold 20,000 shares (20.0K shares) at $32.31 on 2025-05-08, reducing his stake from 262,660 shares to 242,660 shares. This sale occurs against a backdrop of material operational headwinds: the company reported net income of $-39.3M against revenue of $92.8M in the latest quarter, and remains unprofitable on a full-year basis despite posting 27.7% annual revenue growth. The stock has declined 28.7% over the past 90 days and currently trades 44.0% below its 52-week high of $58.88, suggesting the market has moved sharply against growth expectations. While the sale represents a 7.6% reduction in holdings, the C-suite executive retains a substantial 242.7K share position, and the absence of a designated trading plan FLAG permits observation that the timing—following significant price deterioration—warrants investor attention to whether deteriorating profitability or cash position is constraining executive conviction in near-term recovery.